Advances in the Understanding of the Correlation Between Neuroinflammation and Microglia in Alzheimer’s Disease

References

• Yan H, Feng L, Li M. The role of traditional Chinese medicine natural products in beta-Amyloid deposition and tau protein hyperphosphorylation in Alzheimer’s disease. Drug Des Devel Ther. 2023;17:3295–3323. doi:10.2147/DDDT.S380612
   PubMed Web of Science ®Google Scholar
• Azarpazhooh MR, Avan A, Cipriano LE, et al. A third of community-dwelling elderly with intermediate and high level of Alzheimer’s neuropathologic changes are not demented: a meta-analysis. Ageing Res Rev. 2020;58(101002):101002. doi:10.1016/j.arr.2019.101002
   PubMedGoogle Scholar
• Penney J, Ralvenius WT, Tsai LH. Modeling Alzheimer’s disease with iPSC-derived brain cells. Mol Psychiatry. 2020;25(1):148–167. doi:10.1038/s41380-019-0468-3
   PubMed Web of Science ®Google Scholar
• Jiang L, Xu L, Meng X. Recent advance in role of immune system in pathogenesis of Alzheimer’s disease and its immunotherapies. Chin J Neuromed. 2022;(02):200–206. doi:10.3760/cma.j.cn115354-20210925-00627
   Google Scholar
• Nizami S, Hall-Roberts H, Warrier S, Cowley SA, Di Daniel E. Microglial inflammation and phagocytosis in Alzheimer’s disease: potential therapeutic targets. Br J Pharmacol. 2019;176(18):3515–3532. doi:10.1111/bph.14618
   PubMed Web of Science ®Google Scholar
• Herrup K. The case for rejecting the amyloid cascade hypothesis. Nat Neurosci. 2015;18(6):794–799. doi:10.1038/nn.4017
   PubMed Web of Science ®Google Scholar
• Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157–172. doi:10.1038/s41582-020-00435-y
   PubMed Web of Science ®Google Scholar
• Calsolaro V, Edison P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimers Dement. 2016;12(6):719–732. doi:10.1016/j.jalz.2016.02.010
   PubMed Web of Science ®Google Scholar
• Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer’s disease. Curr Opin Neurobiol. 2016;36:74–81. doi:10.1016/j.conb.2015.10.004
   PubMed Web of Science ®Google Scholar
• Wang Q, Sun J, Chen T, et al. Ferroptosis, pyroptosis, and cuproptosis in Alzheimer’s disease. ACS Chem Neurosci. 2023;14(19):3564–3587. doi:10.1021/acschemneuro.3c00343
   PubMed Web of Science ®Google Scholar
• Mangalmurti A, Lukens JR. How neurons die in Alzheimer’s disease: implications for neuroinflammation. Curr Opin Neurobiol. 2022;75:102575. doi:10.1016/j.conb.2022.102575
   PubMed Web of Science ®Google Scholar
• Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018;21(10):1359–1369. doi:10.1038/s41593-018-0242-x
   PubMed Web of Science ®Google Scholar
• Salter M, Stevens W. B. Microglia emerge as central players in brain disease. Nat Med. 2017;23(9):1018–1027. doi:10.1038/nm.4397
   PubMed Web of Science ®Google Scholar
• Ueno M, Fujita Y, Tanaka T, et al. Layer V cortical neurons require microglial support for survival during postnatal development. Nat Neurosci. 2013;16(5):543–551. doi:10.1038/nn.3358
   PubMed Web of Science ®Google Scholar
• Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp Med. 2005;201(4):647–657. doi:10.1084/jem.20041611
   PubMed Web of Science ®Google Scholar
• Roumier A, Béchade C, Poncer JC, et al. Impaired synaptic function in the microglial KARAP/DAP12-deficient mouse. J Neurosci. 2004;24(50):11421–11428. doi:10.1523/JNEUROSCI.2251-04.2004
   PubMed Web of Science ®Google Scholar
• Ji K, Akgul G, Wollmuth LP, Tsirka S. E. Microglia actively regulate the number of functional synapses. PLoS One. 2013;8(2):e56293. doi:10.1371/journal.pone.0056293
   PubMed Web of Science ®Google Scholar
• Jessen KR. Glial cells. Int J Biochem Cell Biol. 2004;36(10):1861–1867. doi:10.1016/j.biocel.2004.02.023
   PubMed Web of Science ®Google Scholar
• Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441–468. doi:10.1146/annurev-immunol-051116-052358
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330(6005):841–845. doi:10.1126/science.1194637
   PubMed Web of Science ®Google Scholar
• Baufeld C, O’Loughlin E, Calcagno N, Madore C, Butovsky O. Differential contribution of microglia and monocytes in neurodegenerative diseases. J Neural Transm. 2018;125(5):809–826. doi:10.1007/s00702-017-1795-7
   PubMed Web of Science ®Google Scholar
• Heneka MT, Carson MJ, El KJ, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405. doi:10.1016/S1474-4422(15)70016-5
   PubMed Web of Science ®Google Scholar
• Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918–934. doi:10.1016/j.cell.2010.02.016
   PubMed Web of Science ®Google Scholar
• Luo XG, Chen SD. The changing phenotype of microglia from homeostasis to disease. Transl Neurodegener. 2012;1(1):9. doi:10.1186/2047-9158-1-9
   PubMedGoogle Scholar
• Subhramanyam CS, Wang C, Hu Q, Dheen ST. Microglia-mediated neuroinflammation in neurodegenerative diseases. Semin Cell Dev Biol. 2019;94:112–120. doi:10.1016/j.semcdb.2019.05.004
   PubMed Web of Science ®Google Scholar
• Jay TR, Hirsch AM, Broihier ML, et al. Disease Progression-Dependent effects of TREM2 deficiency in a mouse model of Alzheimer’s disease. J Neurosci. 2017;37(3):637–647. doi:10.1523/JNEUROSCI.2110-16.2016
   PubMed Web of Science ®Google Scholar
• Ulrich JD, Ulland TK, Mahan TE, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215(4):1047–1058. doi:10.1084/jem.20171265
   PubMed Web of Science ®Google Scholar
• Saeedi-Boroujeni A, Purrahman D, Shojaeian A, Poniatowski LA, Rafiee F, Mahmoudian-Sani MR. Progranulin (PGRN) as a regulator of inflammation and a critical factor in the immunopathogenesis of cardiovascular diseases. J Inflamm. 2023;20(1):1. doi:10.1186/s12950-023-00327-0
   Google Scholar
• Xu W, Tan CC, Cao XP, Tan L. Neuroinflammation modulates the association of PGRN with cerebral amyloid-beta burden. Neurobiol Aging. 2021;103:52–59. doi:10.1016/j.neurobiolaging.2021.02.016
   PubMed Web of Science ®Google Scholar
• Xu W, Han SD, Zhang C, et al. The FAM171A2 gene is a key regulator of progranulin expression and modifies the risk of multiple neurodegenerative diseases. Sci Adv. 2020;6(43). doi:10.1126/sciadv.abb3063
   Web of Science ®Google Scholar
• Zhou X, Sun L, Brady OA, Murphy KA, Hu F. Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency. Acta Neuropathol Commun. 2017;5(1):9. doi:10.1186/s40478-017-0412-1
   PubMedGoogle Scholar
• Van Kampen JM, Baranowski D, Kay DG. Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson’s disease. PLoS One. 2014;9(5):e97032. doi:10.1371/journal.pone.0097032
   PubMed Web of Science ®Google Scholar
• Minami SS, Min SW, Krabbe G, et al. Progranulin protects against amyloid beta deposition and toxicity in Alzheimer’s disease mouse models. Nat Med. 2014;20(10):1157–1164. doi:10.1038/nm.3672
   PubMed Web of Science ®Google Scholar
• Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun. 2015;6:6176. doi:10.1038/ncomms7176
   PubMed Web of Science ®Google Scholar
• Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018;217(2):459–472. doi:10.1083/jcb.201709069
   PubMed Web of Science ®Google Scholar
• Song WM, Joshita S, Zhou Y, Ulland TK, Gilfillan S, Colonna M. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism. J Exp Med. 2018;215(3):745–760. doi:10.1084/jem.20171529
   PubMed Web of Science ®Google Scholar
• Li X, Ni S, Yao Z, Zhang Q. Research progress of TREM2 in Alzheimer’s disease. Chinese Pharmacological Bulletin. 2020;36(08):1049–1053. doi:10.3969/j.issn.1001-1978.2020.08.004
   Google Scholar
• Berner DK, Wessolowski L, Armbrust F, et al. Meprin beta cleaves TREM2 and controls its phagocytic activity on macrophages. FASEB J. 2020;34(5):6675–6687. doi:10.1096/fj.201902183R
   PubMed Web of Science ®Google Scholar
• Zhong L, Chen XF, Wang T, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017;214(3):597–607. doi:10.1084/jem.20160844
   PubMed Web of Science ®Google Scholar
• Konishi H, Kiyama H. Microglial TREM2/DAP12 signaling: a Double-Edged sword in neural diseases. Front Cell Neurosci. 2018;12(206). doi:10.3389/fncel.2018.00206
   PubMedGoogle Scholar
• Ulrich JD, Ulland TK, Colonna M, Holtzman DM. Elucidating the role of TREM2 in Alzheimer’s disease. Neuron. 2017;94(2):237–248. doi:10.1016/j.neuron.2017.02.042
   PubMed Web of Science ®Google Scholar
• Wang Y, Cella M, Mallinson K, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell. 2015;160(6):1061–1071. doi:10.1016/j.cell.2015.01.049
   PubMed Web of Science ®Google Scholar
• Mazaheri F, Snaidero N, Kleinberger G, et al. TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury. EMBO Rep. 2017;18(7):1186–1198. doi:10.15252/embr.201743922
   PubMed Web of Science ®Google Scholar
• Efthymiou AG, Goate AM. Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12(1):43. doi:10.1186/s13024-017-0184-x
   PubMedGoogle Scholar
• Bertram L, Lange C, Mullin K, et al. Genome-wide association analysis reveals putative Alzheimer’s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83(5):623–632. doi:10.1016/j.ajhg.2008.10.008
   PubMed Web of Science ®Google Scholar
• Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–127. doi:10.1056/NEJMoa1211851
   PubMed Web of Science ®Google Scholar
• Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet. 2011;43(5):429–435. doi:10.1038/ng.803
   PubMed Web of Science ®Google Scholar
• Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011;43(5):436–441. doi:10.1038/ng.801
   PubMed Web of Science ®Google Scholar
• Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–116. doi:10.1056/NEJMoa1211103
   PubMed Web of Science ®Google Scholar
• Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7(4):255–266. doi:10.1038/nri2056
   PubMed Web of Science ®Google Scholar
• Ishida A, Akita K, Mori Y, et al. Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33. J Biol Chem. 2014;289(36):25341–25350. doi:10.1074/jbc.M113.523480
   PubMed Web of Science ®Google Scholar
• Linnartz-Gerlach B, Mathews M, Neumann H. Sensing the neuronal glycocalyx by glial sialic acid binding immunoglobulin-like lectins. Neuroscience. 2014;275:113–124. doi:10.1016/j.neuroscience.2014.05.061
   PubMed Web of Science ®Google Scholar
• Cao H, Crocker PR. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology. 2011;132(1):18–26. doi:10.1111/j.1365-2567.2010.03368.x
   PubMed Web of Science ®Google Scholar
• Miles LA, Hermans SJ, Crespi G, et al. Small molecule binding to Alzheimer risk factor CD33 promotes abeta phagocytosis. iScience. 2019;19:110–118. doi:10.1016/j.isci.2019.07.023
   PubMed Web of Science ®Google Scholar
• Joers V, Tansey MG, Mulas G, Carta AR. Microglial phenotypes in Parkinson’s disease and animal models of the disease. Prog Neurobiol. 2017;155:57–75. doi:10.1016/j.pneurobio.2016.04.006
   PubMed Web of Science ®Google Scholar
• Jose S, Groves NJ, Roper KE, Gordon R. Mechanisms of NLRP3 activation and pathology during neurodegeneration. Int J Biochem Cell Biol. 2022;151:106273. doi:10.1016/j.biocel.2022.106273
   PubMed Web of Science ®Google Scholar
• Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9(1):42. doi:10.1186/s40035-020-00221-2
   PubMed Web of Science ®Google Scholar
• Yan M, Jin H, Pan C, Han X. Chronic Microcystin-LR-Induced alpha-Synuclein promotes neuroinflammation through activation of the NLRP3 inflammasome in microglia. Mol Neurobiol. 2023;60(2):884–900. doi:10.1007/s12035-022-03134-5
   PubMed Web of Science ®Google Scholar
• Lawrence G, Holley CL, Schroder K. Parkinson’s disease: connecting mitochondria to inflammasomes. Trends Immunol. 2022;43(11):877–885. doi:10.1016/j.it.2022.09.010
   PubMed Web of Science ®Google Scholar
• Sun G, Zhang R, Liu C, Meng W, Pang Q. Itaconate attenuates neuroinflammation and exerts dopamine neuroprotection in Parkinson’s disease through inhibiting NLRP3 inflammasome. Brain Sci. 2022;12(9):1255. doi:10.3390/brainsci12091255
   PubMed Web of Science ®Google Scholar
• Abderrazak A, Syrovets T, Couchie D, et al. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 2015;4:296–307. doi:10.1016/j.redox.2015.01.008
   PubMed Web of Science ®Google Scholar
• Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6(262). doi:10.3389/fphar.2015.00262
   PubMedGoogle Scholar
• Willingham SB, Allen IC, Bergstralh DT, et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol. 2009;183(3):2008–2015. doi:10.4049/jimmunol.0900138
   PubMed Web of Science ®Google Scholar
• Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–832. doi:10.1016/j.cell.2010.01.040
   PubMed Web of Science ®Google Scholar
• Jorgensen I, Miao EA. Pyroptotic cell death defends against intracellular pathogens. Immunol Rev. 2015;265(1):130–142. doi:10.1111/imr.12287
   PubMed Web of Science ®Google Scholar
• Lechtenberg BC, Mace PD, Riedl SJ. Structural mechanisms in NLR inflammasome signaling. Curr Opin Struct Biol. 2014;29:17–25. doi:10.1016/j.sbi.2014.08.011
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 2006;8(11):1812–1825. doi:10.1111/j.1462-5822.2006.00751.x
   PubMed Web of Science ®Google Scholar
• Ding J, Wang K, Liu W, et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature. 2016;535(7610):111–116. doi:10.1038/nature18590
   PubMed Web of Science ®Google Scholar
• Cai W, Wu T, Chen N. The Amyloid-Beta clearance: from molecular targets to glial and neural cells. Biomolecules. 2023;13(2). doi:10.3390/biom13020313
   Web of Science ®Google Scholar
• Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell. 2017;169(7):1276–1290. doi:10.1016/j.cell.2017.05.018
   PubMed Web of Science ®Google Scholar
• Ulland TK, Song WM, Huang SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease. Cell. 2017;170(4):649–663. doi:10.1016/j.cell.2017.07.023
   PubMed Web of Science ®Google Scholar
• Das R, Chinnathambi S. Microglial remodeling of actin network by Tau oligomers, via G protein-coupled purinergic receptor, P2Y12R-driven chemotaxis. Traffic. 2021;22(5):153–170. doi:10.1111/tra.12784
   PubMed Web of Science ®Google Scholar
• Doran AC, Yurdagul AJ, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020;20(4):254–267. doi:10.1038/s41577-019-0240-6
   PubMed Web of Science ®Google Scholar
• Kuruppu S, Rajapakse NW, Parkington HC, Smith AI. The characteristics of astrocyte on Abeta clearance altered in Alzheimer’s disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. Am J Transl Res. 2017;9(7):3514–3516.
   PubMed Web of Science ®Google Scholar
• Walker DG, Whetzel AM, Serrano G, Sue LI, Beach TG, Lue LF. Association of CD33 polymorphism rs3865444 with Alzheimer’s disease pathology and CD33 expression in human cerebral cortex. Neurobiol Aging. 2015;36(2):571–582. doi:10.1016/j.neurobiolaging.2014.09.023
   PubMed Web of Science ®Google Scholar
• Yuan P, Condello C, Keene CD, et al. TREM2 haplodeficiency in mice and humans impairs the microglia barrier function leading to decreased amyloid compaction and severe axonal dystrophy. Neuron. 2016;90(4):724–739. doi:10.1016/j.neuron.2016.05.003
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wu X, Li X, et al. TREM2 is a receptor for beta-Amyloid that mediates microglial function. Neuron. 2018;97(5):1023–1031. doi:10.1016/j.neuron.2018.01.031
   PubMed Web of Science ®Google Scholar
• Lessard CB, Malnik SL, Zhou Y, et al. High-affinity interactions and signal transduction between Abeta oligomers and TREM2. EMBO Mol Med. 2018;10(11). doi:10.15252/emmm.201809027
   PubMed Web of Science ®Google Scholar
• Wang S, Mustafa M, Yuede CM, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217(9). doi:10.1084/jem.20200785
   Web of Science ®Google Scholar
• Ulrich JD, Finn MB, Wang Y, et al. Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous for TREM2. Mol Neurodegener. 2014;9:20. doi:10.1186/1750-1326-9-20
   PubMed Web of Science ®Google Scholar
• Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667–675. doi:10.1084/jem.20151948
   PubMed Web of Science ®Google Scholar
• Xiang X, Werner G, Bohrmann B, et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med. 2016;8(9):992–1004. doi:10.15252/emmm.201606370
   PubMed Web of Science ®Google Scholar
• Mcquade A, Kang YJ, Hasselmann J, et al. Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease. Nat Commun. 2020;11(1):5370. doi:10.1038/s41467-020-19227-5
   PubMed Web of Science ®Google Scholar
• Zheng H, Jia L, Liu CC, et al. TREM2 promotes microglial survival by activating Wnt/beta-Catenin pathway. J Neurosci. 2017;37(7):1772–1784. doi:10.1523/JNEUROSCI.2459-16.2017
   PubMed Web of Science ®Google Scholar
• Ding X, Wang J, Huang M, et al. Loss of microglial SIRPalpha promotes synaptic pruning in preclinical models of neurodegeneration. Nat Commun. 2021;12(1):2030. doi:10.1038/s41467-021-22301-1
   PubMed Web of Science ®Google Scholar
• Lehrman EK, Wilton DK, Litvina EY, et al. CD47 protects synapses from excess microglia-mediated pruning during development. Neuron. 2018;100(1):120–134. doi:10.1016/j.neuron.2018.09.017
   PubMed Web of Science ®Google Scholar
• Wu C, Yang L, Youngblood H, Liu TC, Duan R. Microglial SIRPalpha deletion facilitates synapse loss in preclinical models of neurodegeneration. Neurosci Bull. 2022;38(2):232–234. doi:10.1007/s12264-021-00795-5
   PubMed Web of Science ®Google Scholar
• Zhong L, Sheng X, Wang W, et al. TREM2 receptor protects against complement-mediated synaptic loss by binding to complement C1q during neurodegeneration. Immunity. 2023;56(8):1794–1808. doi:10.1016/j.immuni.2023.06.016
   PubMed Web of Science ®Google Scholar
• Yin C, Ackermann S, Ma Z, et al. ApoE attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med. 2019;25(3):496–506. doi:10.1038/s41591-018-0336-8
   PubMed Web of Science ®Google Scholar
• Zhang W, Xiao D, Mao Q, Xia H. Role of neuroinflammation in neurodegeneration development. Signal Transduct Target Ther. 2023;8(1):267. doi:10.1038/s41392-023-01486-5
   PubMed Web of Science ®Google Scholar
• Ferri E, Rossi PD, Geraci A, Ciccone S, Cesari M, Arosio B. The sTREM2 concentrations in the blood: a marker of neurodegeneration? Front Mol Biosci. 2020;7:627931. doi:10.3389/fmolb.2020.627931
   PubMed Web of Science ®Google Scholar
• Gu L, Shu H, Wang Y. Soluble TREM2 in body fluid in Alzheimer’s disease and Parkinson’s disease. Neurol Sci. 2023;44(8):2743–2751. doi:10.1007/s10072-023-06729-5
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhong X, Wang L, et al. Effects of soluble TREM2 on motor progression in Parkinson’s disease. Neurosci Lett. 2023;807:137277. doi:10.1016/j.neulet.2023.137277
   PubMed Web of Science ®Google Scholar
• van der Ende EL, Morenas-Rodriguez E, Mcmillan C, et al. CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiol Aging. 2021;103:151–158. doi:10.1016/j.neurobiolaging.2021.02.024
   Web of Science ®Google Scholar
• Weber GE, Khrestian M, Tuason ED, et al. Peripheral sTREM2-Related inflammatory activity alterations in Early-Stage Alzheimer’s disease. J Immunol. 2022;208(10):2283–2299. doi:10.4049/jimmunol.2100771
   PubMed Web of Science ®Google Scholar
• Rauchmann BS, Schneider-Axmann T, Alexopoulos P, Perneczky R. CSF soluble TREM2 as a measure of immune response along the Alzheimer’s disease continuum. Neurobiol Aging. 2019;74:182–190. doi:10.1016/j.neurobiolaging.2018.10.022
   PubMed Web of Science ®Google Scholar
• Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566–581. doi:10.1016/j.immuni.2017.08.008
   PubMed Web of Science ®Google Scholar
• Zhong L, Xu Y, Zhuo R, et al. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer’s disease model. Nat Commun. 2019;10(1):1365. doi:10.1038/s41467-019-09118-9
   PubMed Web of Science ®Google Scholar
• Carosi JM, Sargeant TJ. Rapamycin and Alzheimer disease: a double-edged sword? Autophagy. 2019;15(8):1460–1462. doi:10.1080/15548627.2019.1615823
   PubMed Web of Science ®Google Scholar
• Ising C, Venegas C, Zhang S, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669–673. doi:10.1038/s41586-019-1769-z
   PubMed Web of Science ®Google Scholar
• van Olst L, Verhaege D, Franssen M, et al. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model. Neurobiol Aging. 2020;89:89–98. doi:10.1016/j.neurobiolaging.2020.01.003
   PubMed Web of Science ®Google Scholar
• Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron. 2013;78(4):631–643. doi:10.1016/j.neuron.2013.04.014
   PubMed Web of Science ®Google Scholar
• Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM. Expression of novel Alzheimer’s disease risk genes in control and Alzheimer’s disease brains. PLoS One. 2012;7(11):e50976. doi:10.1371/journal.pone.0050976
   PubMed Web of Science ®Google Scholar
• Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001;158(2):277–287. doi:10.1016/s0021-9150(01)00433-6
   PubMed Web of Science ®Google Scholar
• Ramsborg CG, Papoutsakis ET. Global transcriptional analysis delineates the differential inflammatory response interleukin-15 elicits from cultured human T cells. Exp Hematol. 2007;35(3):454–464. doi:10.1016/j.exphem.2006.11.013
   PubMed Web of Science ®Google Scholar
• Griciuc A, Federico AN, Natasan J, et al. Gene therapy for Alzheimer’s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet. 2020;29(17):2920–2935. doi:10.1093/hmg/ddaa179
   PubMed Web of Science ®Google Scholar
• Jiang T, Yu JT, Hu N, Tan MS, Zhu XC, Tan L. CD33 in Alzheimer’s disease. Mol Neurobiol. 2014;49(1):529–535. doi:10.1007/s12035-013-8536-1
   PubMed Web of Science ®Google Scholar
• Malik M, Simpson JF, Parikh I, et al. CD33 Alzheimer’s risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci. 2013;33(33):13320–13325. doi:10.1523/JNEUROSCI.1224-13.2013
   PubMed Web of Science ®Google Scholar
• Raj T, Ryan KJ, Replogle JM, et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer’s disease susceptibility. Hum Mol Genet. 2014;23(10):2729–2736. doi:10.1093/hmg/ddt666
   PubMed Web of Science ®Google Scholar
• Tortora F, Rendina A, Angiolillo A, et al. CD33 rs2455069 SNP: correlation with Alzheimer’s disease and hypothesis of functional role. Int J Mol Sci. 2022;23(7):3629. doi:10.3390/ijms23073629
   PubMed Web of Science ®Google Scholar
• Eskandari-Sedighi G, Jung J, Macauley MS. CD33 isoforms in microglia and Alzheimer’s disease: friend and foe. Mol Aspects Med. 2023;90:101111. doi:10.1016/j.mam.2022.101111
   PubMed Web of Science ®Google Scholar
• Malik M, Chiles JR, Xi HS, et al. Genetics of CD33 in Alzheimer’s disease and acute myeloid leukemia. Hum Mol Genet. 2015;24(12):3557–3570. doi:10.1093/hmg/ddv092
   PubMed Web of Science ®Google Scholar
• Griciuc A, Patel S, Federico AN, et al. TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer’s disease. Neuron. 2019;103(5):820–835. doi:10.1016/j.neuron.2019.06.010
   PubMed Web of Science ®Google Scholar
• Salminen A, Kaarniranta K, Kauppinen A. Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: potential role in Alzheimer’s pathogenesis. Neurochem Int. 2021;150(105186):105186. doi:10.1016/j.neuint.2021.105186
   PubMedGoogle Scholar
• Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation. 2013;127(22):2222–2230. doi:10.1161/CIRCULATIONAHA.113.002033
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Ravandi F, Daver N. Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018;25(2):136–145. doi:10.1097/MOH.0000000000000401
   PubMed Web of Science ®Google Scholar
• Egan PC, Reagan JL. The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia. Onco Targets Ther. 2018;11:8265–8272. doi:10.2147/OTT.S150807
   PubMed Web of Science ®Google Scholar
• Jurcic JG. What happened to anti-CD33 therapy for acute myeloid leukemia? Curr Hematol Malig Rep. 2012;7(1):65–73. doi:10.1007/s11899-011-0103-0
   PubMed Web of Science ®Google Scholar
• Lambert J, Pautas C, Terre C, et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, Phase III ALFA-0701 trial. Haematologica. 2019;104(1):113–119. doi:10.3324/haematol.2018.188888
   PubMed Web of Science ®Google Scholar
• Zhao L. CD33 in Alzheimer’s disease - biology, pathogenesis, and therapeutics: a Mini-Review. Gerontology. 2019;65(4):323–331. doi:10.1159/000492596
   PubMed Web of Science ®Google Scholar
• Feng YS, Tan ZX, Wu LY, Dong F, Zhang F. The involvement of NLRP3 inflammasome in the treatment of Alzheimer’s disease. Ageing Res Rev. 2020;64(101192). doi:10.1016/j.arr.2020.101192
   PubMedGoogle Scholar
• Jha D, Bakker E, Kumar R. Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer’s disease. J Neurochem. 2023. doi:10.1111/jnc.15788
   PubMed Web of Science ®Google Scholar
• Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857–865. doi:10.1038/ni.1636
   PubMed Web of Science ®Google Scholar
• Bai H, Zhang Q. Activation of NLRP3 inflammasome and onset of Alzheimer’s disease. Front Immunol. 2021;12(701282). doi:10.3389/fimmu.2021.701282
   Google Scholar
• Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674–678. doi:10.1038/nature11729
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai Y, Fu Y, et al. Salidroside ameliorates Alzheimer’s disease by targeting NLRP3 Inflammasome-Mediated pyroptosis. Front Aging Neurosci. 2021;13:809433. doi:10.3389/fnagi.2021.809433
   PubMed Web of Science ®Google Scholar
• Chiu YJ, Lin CH, Lee MC, et al. Formulated Chinese medicine Shaoyao Gancao Tang reduces NLRP1 and NLRP3 in Alzheimer’s disease cell and mouse models for neuroprotection and cognitive improvement. Aging. 2021;13(11):15620–15637. doi:10.18632/aging.203125
   PubMedGoogle Scholar
• Xu Z, Zhou X, Hong X, et al. Essential oil of Acorus tatarinowii Schott inhibits neuroinflammation by suppressing NLRP3 inflammasome activation in 3 x Tg-AD transgenic mice. Phytomedicine. 2023;112:154695. doi:10.1016/j.phymed.2023.154695
   PubMed Web of Science ®Google Scholar
• Ben-Menachem-Zidon O, Ben-Menahem Y, Ben-Hur T, Yirmiya R. Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimer’s disease model. Neuropsychopharmacol. 2014;39(2):401–414. doi:10.1038/npp.2013.208
   PubMed Web of Science ®Google Scholar
• Fernandez PL, Britton GB, Rao KS. Potential immunotargets for Alzheimer’s disease treatment strategies. J Alzheimers dis. 2013;33(2):297–312. doi:10.3233/JAD-2012-121222
   PubMed Web of Science ®Google Scholar
• Craft JM, Watterson DM, Frautschy SA, Van Eldik LJ. Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging. 2004;25(10):1283–1292. doi:10.1016/j.neurobiolaging.2004.01.006
   PubMed Web of Science ®Google Scholar
• Craft JM, Van Eldik LJ, Zasadzki M, Hu W, Watterson DM. Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci. 2004;24(1):115–122. doi:10.1385/JMN:24:1:115
   PubMed Web of Science ®Google Scholar
• Hu W, Ralay RH, Craft JM, Van Eldik LJ, Watterson DM. Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer’s disease-related mouse model. Curr Alzheimer Res. 2005;2(2):197–205. doi:10.2174/1567205053585828
   PubMedGoogle Scholar
• Mirzoeva S, Sawkar A, Zasadzki M, et al. Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem. 2002;45(3):563–566. doi:10.1021/jm015573g
   PubMed Web of Science ®Google Scholar
• Vandenabeele P, Fiers W. Is amyloidogenesis during Alzheimer’s disease due to an IL-1-/IL-6-mediated ‘acute phase response’ in the brain? Immunol Today. 1991;12(7):217–219. doi:10.1016/0167-5699(91)90032-O
   PubMedGoogle Scholar
• Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging. 2001;22(6):903–908. doi:10.1016/s0197-4580(01)00287-1
   PubMed Web of Science ®Google Scholar
• Huang Z, Xie L, Li H, et al. Insight into interleukin-37: the potential therapeutic target in allergic diseases. Cytokine Growth Factor Rev. 2019;49:32–41. doi:10.1016/j.cytogfr.2019.10.003
   PubMed Web of Science ®Google Scholar
• Terrando N, Rei FA, Vizcaychipi M, et al. The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit Care. 2010;14(3):R88. doi:10.1186/cc9019
   PubMed Web of Science ®Google Scholar
• Craft JM, Watterson DM, Hirsch E, Van Eldik LJ. Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human beta-amyloid. J Neuroinflammation. 2005;2:15. doi:10.1186/1742-2094-2-15
   PubMed Web of Science ®Google Scholar
• Huang ZB, Sheng GQ. Interleukin-1beta with learning and memory. Neurosci Bull. 2010;26(6):455–468. doi:10.1007/s12264-010-6023-5
   PubMed Web of Science ®Google Scholar
• Lynch MA. Neuroinflammatory changes negatively impact on LTP: a focus on IL-1beta. Brain Res. 2015;1621:197–204. doi:10.1016/j.brainres.2014.08.040
   PubMed Web of Science ®Google Scholar
• Kitazawa M, Cheng D, Tsukamoto MR, et al. Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer’s disease model. J Immunol. 2011;187(12):6539–6549. doi:10.4049/jimmunol.1100620
   PubMed Web of Science ®Google Scholar
• Sutinen EM, Pirttila T, Anderson G, Salminen A, Ojala JO. Pro-inflammatory interleukin-18 increases Alzheimer’s disease-associated amyloid-beta production in human neuron-like cells. J Neuroinflammation. 2012;9:199. doi:10.1186/1742-2094-9-199
   PubMed Web of Science ®Google Scholar
• Ojala J, Alafuzoff I, Herukka SK, van Groen T, Tanila H, Pirttila T. Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients. Neurobiol Aging. 2009;30(2):198–209. doi:10.1016/j.neurobiolaging.2007.06.006
   PubMed Web of Science ®Google Scholar
• Ojala JO, Sutinen EM, Salminen A, Pirttila T. Interleukin-18 increases expression of kinases involved in tau phosphorylation in SH-SY5Y neuroblastoma cells. J Neuroimmunol. 2008;205(1–2):86–93. doi:10.1016/j.jneuroim.2008.09.012
   PubMed Web of Science ®Google Scholar
• Zhang J, Song T, Liang H, Lian J, Zhang G, Gong H. Interleukin-18 −137 G/C and −607 C/A polymorphisms and Alzheimer’s disease risk: a meta-analysis. Neurol Sci. 2016;37(6):921–927. doi:10.1007/s10072-016-2516-y
   PubMed Web of Science ®Google Scholar
• Boyd RJ, Avramopoulos D, Jantzie LL, Mccallion AS. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J Neuroinflammation. 2022;19(1):223. doi:10.1186/s12974-022-02584-x
   PubMed Web of Science ®Google Scholar
• Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18. doi:10.1186/s12929-019-0609-7
   PubMed Web of Science ®Google Scholar
• Huang LK, Kuan YC, Lin HW, Hu CJ. Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. J Biomed Sci. 2023;30(1):83. doi:10.1186/s12929-023-00976-6
   PubMed Web of Science ®Google Scholar
• Cui W, Sun C, Ma Y, Wang S, Wang X, Zhang Y. Inhibition of TLR4 Induces M2 Microglial Polarization and Provides Neuroprotection via the NLRP3 Inflammasome in Alzheimer’s Disease. Front Neurosci. 2020;14:444. doi:10.3389/fnins.2020.00444
   PubMed Web of Science ®Google Scholar
• Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer’s disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cognit Disord. 2010;30(2):131–146. doi:10.1159/000318845
   PubMed Web of Science ®Google Scholar
• Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry. 2010;68(10):930–941. doi:10.1016/j.biopsych.2010.06.012
   PubMed Web of Science ®Google Scholar
• Lai KSP, Liu CS, Rau A, et al. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry. 2017;88(10):876–882. doi:10.1136/jnnp-2017-316201
   PubMed Web of Science ®Google Scholar
• Lananna BV, McKee CA, King MW, et al. S. Chi3l1/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer’s disease pathogenesis. Sci Transl Med. 2020;12(574):eaax3519. doi:10.1126/scitranslmed.aax3519
   PubMed Web of Science ®Google Scholar
• Alcolea D, Martínez-Lage P, Sánchez-Juan P, et al. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology. 2015;85(7):626–633. doi:10.1212/WNL.0000000000001859
   PubMed Web of Science ®Google Scholar
• Stefaniak J, O’Brien J. Imaging of neuroinflammation in dementia: a review. J Neurol Neurosurg Psychiatry. 2016;87(1):21–28. doi:10.1136/jnnp-2015-311336
   PubMed Web of Science ®Google Scholar
• Parbo P, Ismail R, Hansen KV, et al. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer’s disease. Brain. 2017;140(7):2002–2011. doi:10.1093/brain/awx120
   PubMedGoogle Scholar
• Chen H, Guo Z, Gao X, Dai X. Progress in investigating the role of microglia in Alzheimer’s disease. Chinese Bulletin of Life Sic. 2022;34(07):830–837. doi:10.13376/j.cbls/2022091
   Google Scholar